Stifel Nicolaus Boosts Artivion (NYSE:AORT) Price Target to $30.00

Artivion (NYSE:AORT) had its price target upped by Stifel Nicolaus from $28.00 to $30.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently weighed in on AORT. Needham & Company LLC restated a buy rating and set a $30.00 price target on shares of Artivion in a report on Friday, August 9th. Oppenheimer increased their price objective on Artivion from $25.00 to $30.00 and gave the company an outperform rating in a report on Friday, August 9th. Finally, Lake Street Capital boosted their target price on Artivion from $28.00 to $30.00 and gave the stock a buy rating in a report on Tuesday, July 2nd.

Artivion Stock Up 0.6 %

AORT stock opened at $25.39 on Friday. The company’s 50 day simple moving average is $26.14 and its 200-day simple moving average is $23.54. Artivion has a 52-week low of $12.16 and a 52-week high of $29.24. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.63 and a quick ratio of 4.04. The firm has a market capitalization of $1.06 billion, a P/E ratio of -105.79 and a beta of 1.74.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. As a group, equities research analysts anticipate that Artivion will post 0.2 EPS for the current year.

Insider Activity

In related news, Director Anthony B. Semedo sold 9,709 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares in the company, valued at approximately $853,633.41. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Artivion news, Director Anthony B. Semedo sold 9,709 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the transaction, the director now owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 2,383 shares of Artivion stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $25.76, for a total value of $61,386.08. Following the sale, the senior vice president now directly owns 165,099 shares in the company, valued at approximately $4,252,950.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,679 shares of company stock valued at $626,518. 8.10% of the stock is owned by company insiders.

Institutional Trading of Artivion

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AORT. The Manufacturers Life Insurance Company boosted its holdings in Artivion by 3.2% during the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after purchasing an additional 481 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Artivion by 38.6% during the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after acquiring an additional 505 shares during the last quarter. Louisiana State Employees Retirement System lifted its position in Artivion by 3.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after purchasing an additional 600 shares during the period. Texas Permanent School Fund Corp lifted its holdings in Artivion by 2.0% in the first quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock valued at $722,000 after buying an additional 677 shares during the period. Finally, nVerses Capital LLC bought a new position in shares of Artivion in the 2nd quarter worth $28,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.